Physician

Ivor John Percent, M.D.

According to 2025 Medicare claims, Ivor Percent, M.D. (NPI: 1619053998) practices hematology/oncology in the Punta Gorda, FL market, with the plurality of this provider's patient population coming from Charlotte, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33980-2012.

Percent's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,991 traditional Medicare patients, billed 494,512 HCPCS/CPT codes, and received $7,481,088 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,648 prescription claims across 382 beneficiaries totaling $5,398,331 in drug costs, led by Revlimid (Lenalidomide). 2022 DME data shows 48 claims. Open Payments data shows 215 records totaling $284,119. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $1,883,105 to $5,398,331. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $24,432 to $1,663.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,906	482,913	$4,939,390
2016	1,797	501,005	$5,026,014
2017	1,986	553,929	$5,530,803
2018	1,993	661,523	$7,202,474
2019	2,143	742,178	$8,137,650
2020	1,482	666,976	$7,487,208
2021	1,755	465,415	$6,508,987
2022	1,622	390,688	$5,431,677
2023	1,698	416,978	$4,924,827
2024	1,991	494,512	$7,481,088

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	374	1,640	$1,883,105
2016	409	1,896	$2,487,382
2017	399	1,747	$2,786,616
2018	415	1,842	$3,637,648
2019	435	1,780	$4,073,267
2020	404	1,762	$4,323,820
2021	359	1,638	$4,621,575
2022	299	1,222	$4,493,711
2023	298	1,096	$3,499,254
2024	382	1,648	$5,398,331

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	183	$44,600
2016	N/R	62	$2,913
2017	N/R	44	$9,380
2018	12	80	$14,295
2019	N/R	99	$10,981
2020	N/R	65	$4,465
2021	N/R	31	$1,742
2022	N/R	48	$1,165
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	907	1,931	$94
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	707	1,312	$13
96372	Injection of drug or substance under skin or into muscle	460	1,494	$10
36415	Insertion of needle into vein for collection of blood sample	1,369	3,735	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	1,301	3,645	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	118	3,282	$2,247,559
Pomalyst	Pomalidomide	22	616	$481,871
Xtandi	Enzalutamide	30	900	$420,142
Imbruvica	Ibrutinib	24	672	$386,137
Besremi	Ropeginterferon Alfa-2b-Njft	12	336	$205,412

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	162	$3,420	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	53	$280,699	Eisai Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ivor John Percent, M.D.?

Tedicare shows public-source Medicare data for Ivor John Percent, M.D. (NPI 1619053998), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ivor John Percent, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ivor John Percent, M.D.?

Ivor John Percent, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Ivor John Percent, M.D. have Open Payments data?

Ivor John Percent, M.D. has 215 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.